Results 141 to 150 of about 79,111 (213)

Potential Hepatoprotective Effects of Irbesartan, an Accessible Angiotensin II Receptor Blocker, Against Cisplatin-Induced Liver Injury in a Rat Model. [PDF]

Turk J Pharm Sci
Ertunç O, Erzurumlu Y, Savran M, Çataklı D, Doğan Kıran E, Pekgöz Ş.   +5 more
europepmc   +1 more source

Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19. [PDF]

Am J Cardiol, 2020
Bae DJ, Tehrani DM, Rabadia SV, Frost M, Parikh RV, Calfon-Press M, Aksoy O, Umar S, Ardehali R, Rabbani A, Bokhoor P, Nsair A, Currier J, Tobis J, Fonarow GC, Dave R, Rafique AM.   +16 more
europepmc   +1 more source

Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan. [PDF]

Circ Heart Fail, 2019
Clements RT, Vang A, Fernandez-Nicolas A, Kue NR, Mancini TJ, Morrison AR, Mallem K, McCullough DJ, Choudhary G.   +8 more
europepmc   +1 more source

Erratum to renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis. [PDF]

Ann Transl Med, 2020
Wu D, Bai J, Cui S, Fu B, Yin Z, Cai G, Chen X.   +6 more
europepmc   +1 more source

Correction to: Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy‑associated cardiomyopathy. [PDF]

Cell Biosci, 2020
Wang Y, Guo Z, Gao Y, Liang P, Shan Y, He J.   +5 more
europepmc   +1 more source

Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. [PDF]

J Infect Dis, 2020
Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu SK, Skopicki HA, Singer AJ, Duong TQ.   +9 more
europepmc   +1 more source

Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. [PDF]

J Geriatr Cardiol, 2020
Lyu SQ, Yang YM, Zhu J, Wang J, Wu S, Ren JM, Zhang H, Shao XH.   +7 more
europepmc   +1 more source

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. [PDF]

Eur J Heart Fail, 2020
Lebek S, Tafelmeier M, Messmann R, Provaznik Z, Schmid C, Maier LS, Birner C, Arzt M, Wagner S.   +8 more
europepmc   +1 more source

ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease [PDF]

, 2016
Adams LG, Adams LG, Barber PJ, Benigni A, Cowgill Ld, Cowgill LD, DiBartola SP, Finco DR, Goldstein RE, Grandy JL, Jensen J, Kirk CA, Lulich JP, Ross LA, Seefeldt SL, Sparkes AH, Steele JL, Stiles J, Tonkin L, Wagner E   +19 more
core   +1 more source

Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. [PDF]

Gastroenterology, 2020
Tan ND, Qiu Y, Xing XB, Ghosh S, Chen MH, Mao R.   +5 more
europepmc   +1 more source